Mark A. Rothstein
Research Subjects
Research Interests
Mark A. Rothstein has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Julia Irzyk
3 shared publicationsMeghan K. Talbott
The authors are with the Institute for Bioethics, Health Policy and Law, University of Louisville, School of Medicine, Louisville, Ky
3 shared publicationsAbigail B. Shoben
The Ohio State University
2 shared publicationsBartha Maria Knoppers
McGill Univ, Ctr Genom & Policy, Montreal, PQ, Canada
2 shared publications- Ellen Wright Clayton
Center for Biomedical Ethics and Society, Vanderbilt University Medical Center , Nashville, TN 37203
2 shared publications Gary E. Marchant
Center for Law, Science & Innovation, Sandra Day O'Connor College of Law, Arizona State University, Phoenix, AZ 85004, USA
2 shared publications
Latest Publications
- 1 October 2023
- Published by American Public Health Association in American Journal of Public Health
- Vol. 113 (10) , 1037-1039
US Supreme Court Doctrines in COVID-19 Cases Threaten Public Health
- 1 October 2023
- Published by American Public Health Association in American Journal of Public Health
- Vol. 113 (10) , 1037-1039
US Supreme Court Doctrines in COVID-19 Cases Threaten Public Health
- 1 October 2023
- Published by American Public Health Association in American Journal of Public Health
- Vol. 113 (10) , 1055-1058
Translational Bioethics and Public Health
- 1 October 2023
- Published by American Public Health Association in American Journal of Public Health
- Vol. 113 (10) , 1055-1058
Translational Bioethics and Public Health
- 27 May 2023
- Published by Elsevier in The Journal of Pediatrics
- Vol. 260, 113524
Concordance of International Regulation of Pediatric Health Research
- 27 May 2023
- Published by Elsevier in The Journal of Pediatrics
- Vol. 260, 113524
Concordance of International Regulation of Pediatric Health Research
- 3 January 2023
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 66 (2) , 267-277
The Illusion of Health Privacy in Obstetrics-Gynecology
Many health professionals and patients erroneously believe that professional ethics and laws protect the privacy of sensitive records in obstetrics-gynecology. The Health Insurance Portability and Accountability Act Privacy Rule permits disclosure of health records without authorization for public health, law enforcement, and other reasons. Individuals also may be compelled to authorize the release of their records in applying for employment, life insurance, or government benefits. Disclosure of sensitive health information has increased because of comprehensive electronic health records, patient-developed data from mobile devices, consolidation of medical practices, and law enforcement interest in reproductive health records attributable to the change in abortion laws.
- 3 January 2023
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 66 (2) , 267-277
The Illusion of Health Privacy in Obstetrics-Gynecology
Many health professionals and patients erroneously believe that professional ethics and laws protect the privacy of sensitive records in obstetrics-gynecology. The Health Insurance Portability and Accountability Act Privacy Rule permits disclosure of health records without authorization for public health, law enforcement, and other reasons. Individuals also may be compelled to authorize the release of their records in applying for employment, life insurance, or government benefits. Disclosure of sensitive health information has increased because of comprehensive electronic health records, patient-developed data from mobile devices, consolidation of medical practices, and law enforcement interest in reproductive health records attributable to the change in abortion laws.
- 18 November 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (3) , 603-607
Expanding the Role of Bioethics in Translational Science
Translational science attempts to accelerate and increase the significance of research progressing from bench to bedside. Support from the NIH through its institutional grant program has increased the prominence and importance of translational science. The inclusion of a broadly based bioethics component to translational science presents an opportunity for bioethics scholars to address fundamental social issues, including the effects of translational science on public health, health equity, and human flourishing. Large-scale bioethical inquiries could examine research priorities, unintended consequences of research, and access to and uptake of research discoveries.
- 18 November 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (3) , 603-607
Expanding the Role of Bioethics in Translational Science
Translational science attempts to accelerate and increase the significance of research progressing from bench to bedside. Support from the NIH through its institutional grant program has increased the prominence and importance of translational science. The inclusion of a broadly based bioethics component to translational science presents an opportunity for bioethics scholars to address fundamental social issues, including the effects of translational science on public health, health equity, and human flourishing. Large-scale bioethical inquiries could examine research priorities, unintended consequences of research, and access to and uptake of research discoveries.
- 27 July 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (2) , 368-374
TheOSHA COVID-19 Caseand the Scope of the Occupational Safety and Health Act
The Occupational Safety and Health Administration (OSHA) issued an emergency temporary standard (ETS) for COVID-19 applicable to private sector employers with 100 or more employees. Among other things, the ETS required employers either to mandate employee vaccination or weekly testing and wearing masks.
- 27 July 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (2) , 368-374
TheOSHA COVID-19 Caseand the Scope of the Occupational Safety and Health Act
The Occupational Safety and Health Administration (OSHA) issued an emergency temporary standard (ETS) for COVID-19 applicable to private sector employers with 100 or more employees. Among other things, the ETS required employers either to mandate employee vaccination or weekly testing and wearing masks.
- 4 March 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (1) , 184-189
Physician Liability for Suicide after Negligent Tapering of Opioids
The precipitous and medically contraindicated reduction or “tapering” of opioids for patients with chronic pain due to serious medical conditions has caused needless suffering and, increasingly, suicide. Physicians could be liable for wrongful death based on negligent tapering of opioids.
- 4 March 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (1) , 184-189
Physician Liability for Suicide after Negligent Tapering of Opioids
The precipitous and medically contraindicated reduction or “tapering” of opioids for patients with chronic pain due to serious medical conditions has caused needless suffering and, increasingly, suicide. Physicians could be liable for wrongful death based on negligent tapering of opioids.
- 3 February 2022
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 9 (6) , 2146-2156
Cardiologists’ Perspectives on BiDil and the Use of Race in Drug Prescribing
Objectives We explored cardiologists’ attitudes and prescribing patterns specific to the use of generic isosorbide dinitrate and hydralazine hydrochloride, and the fixed-dose patented drug, BiDil. Background Since the Food and Drug Administration approved BiDil in 2005 with an indication for self-identified black patients, disagreement about the appropriateness of race-based drugs has intensified and led to calls for providers and researchers to abandon race-based delimitations. This paper reports empirical evidence of cardiologists’ views on BiDil’s race-based indication and their ongoing inertia with respect to the debate about BiDil. Methods We conducted a 2010 cross-sectional online survey of members of the Association of Black Cardiologists. Results Fifty-nine cardiologists responded to the survey. Most participants (62.7%) prescribed BiDil to their patients. More than 40% of respondents did not prescribe BiDil to any non-African Americans. When considering whether to prescribe BiDil, a patient’s race determined by physician assessment was the third most important factor considered by participants. The majority of participants (72.7%) selected symptoms as the most important factor. Most participants (59.2%) perceived race as defining biologically distinct individuals. Respondents prescribed BiDil more often to African American patients than non-African American patients. However, they prescribed the generic components that makeup BiDil to African Americans and non-African American patients similarly. Conclusions The survey provides useful findings that, when viewed within the context of ongoing debates about race-based medicine, show little progress toward appropriately utilizing BiDil to maximize health outcomes, yet, might inform the development of practical and effective guidelines concerning the use of race in medicine.
- 3 February 2022
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 9 (6) , 2146-2156
Cardiologists’ Perspectives on BiDil and the Use of Race in Drug Prescribing
Objectives We explored cardiologists’ attitudes and prescribing patterns specific to the use of generic isosorbide dinitrate and hydralazine hydrochloride, and the fixed-dose patented drug, BiDil. Background Since the Food and Drug Administration approved BiDil in 2005 with an indication for self-identified black patients, disagreement about the appropriateness of race-based drugs has intensified and led to calls for providers and researchers to abandon race-based delimitations. This paper reports empirical evidence of cardiologists’ views on BiDil’s race-based indication and their ongoing inertia with respect to the debate about BiDil. Methods We conducted a 2010 cross-sectional online survey of members of the Association of Black Cardiologists. Results Fifty-nine cardiologists responded to the survey. Most participants (62.7%) prescribed BiDil to their patients. More than 40% of respondents did not prescribe BiDil to any non-African Americans. When considering whether to prescribe BiDil, a patient’s race determined by physician assessment was the third most important factor considered by participants. The majority of participants (72.7%) selected symptoms as the most important factor. Most participants (59.2%) perceived race as defining biologically distinct individuals. Respondents prescribed BiDil more often to African American patients than non-African American patients. However, they prescribed the generic components that makeup BiDil to African Americans and non-African American patients similarly. Conclusions The survey provides useful findings that, when viewed within the context of ongoing debates about race-based medicine, show little progress toward appropriately utilizing BiDil to maximize health outcomes, yet, might inform the development of practical and effective guidelines concerning the use of race in medicine.
- 1 February 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (2) , 499-500
Correspondence on “Exploring the motivations of research participants who chose not to learn medically actionable secondary findings about themselves” by Schupmann et al
- 1 February 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (2) , 499-500
Correspondence on “Exploring the motivations of research participants who chose not to learn medically actionable secondary findings about themselves” by Schupmann et al
- 1 January 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (4) , 841-847
Doctors and Pain Patients Avoid “Ruan” in the Supreme Court
Physicians’ fear of criminal prosecution for prescribing opioid analgesics is a major reason why many chronic pain patients are having an increasingly difficult time obtaining medically appropriate pain relief. In Ruan v. United States, 142 S. Ct. 2370 (2022), the Supreme Court unanimously vacated two federal convictions under the Controlled Substances Act. The Court held that the government must prove that the defendant knowingly or intentionally acted in an unauthorized manner.
- 1 January 2022
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 50 (4) , 841-847
Doctors and Pain Patients Avoid “Ruan” in the Supreme Court
Physicians’ fear of criminal prosecution for prescribing opioid analgesics is a major reason why many chronic pain patients are having an increasingly difficult time obtaining medically appropriate pain relief. In Ruan v. United States, 142 S. Ct. 2370 (2022), the Supreme Court unanimously vacated two federal convictions under the Controlled Substances Act. The Court held that the government must prove that the defendant knowingly or intentionally acted in an unauthorized manner.